FDA has approved 19 companion diagnostics for 13 drugs. Stakeholders contacted by BioCentury expressed concern that the agency's resources could be overwhelmed simply by reviewing applications for LDTs for the same intended use as the approved companion diagnostics. Individual diagnostic sales were not available, except for FerriScan R2-MRI, for which Resonance Health Ltd. (ASX:RHT) reported A$1.1 million ($1 million) in revenues for the fiscal